SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Elite football players 'more likely to develop dementia'
Fri March 17th - Elite male footballers are more likely to develop dementia than the general population, according to a Swedish study published today. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

New drug promise for people with hand osteoarthritis

Thursday December 22nd 2022

A new drug has shown promise as a candidate to help prevent hand osteoarthritis, a study has found.

Researchers at the University of Oxford, UK, suspected talarozole, a drug that increases retinoic acid, could prevent the condition in disease models.

They investigated a common gene variant that had been linked to severe hand OA and using patient samples collected at the time of routine hand surgery, as well as a number of experimental models, they identified retinoic acid was especially low in ‘at risk’ individuals.

The findings are published in *Science Translational Medicine*.

Tonia Vincent, Professor of musculoskeletal biology & honorary rheumatologist at Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), said: “Hand osteoarthritis is a common and debilitating medical condition that affects mainly women, especially around the time of the menopause. We currently have no effective treatments that modify their disease”

As talarozole has an acceptable safety profile in human subjects, a small proof of concept clinical study is now under way to see if it could be a disease modifying treatment.

Dr Neha Issar-Brown, director of research and health intelligence at the charity Versus Arthritis, which funded the research, said: “There is an urgent need for disease-modifying treatments designed to prevent or reverse the painful symptoms of OA. This study reveals a new understanding of the causes of hand osteoarthritis, which could lead to identifying new biological targets for intervention in hand OA.

“This research is still at an early stage, but with these encouraging findings we are a big step closer in being able to develop a new class of disease-modifying drugs to treat osteoarthritis, prevent chronic pain, and enable people to live well with the condition.”

Variants in ALDH1A2[Q1] reveal an anti-inflammatory role for retinoic acid and a new class of disease-modifying drugs in osteoarthritis. *Science Translational Medicine* 21 December 2022

Tags: Rheumatology | UK News

Printer friendly page Printer friendly page

CATEGORIES